WO2007017291A2 - Realisation d'une solution d'oxaliplatine et contenant et jeu de contenants avec cette solution - Google Patents
Realisation d'une solution d'oxaliplatine et contenant et jeu de contenants avec cette solution Download PDFInfo
- Publication number
- WO2007017291A2 WO2007017291A2 PCT/EP2006/007982 EP2006007982W WO2007017291A2 WO 2007017291 A2 WO2007017291 A2 WO 2007017291A2 EP 2006007982 W EP2006007982 W EP 2006007982W WO 2007017291 A2 WO2007017291 A2 WO 2007017291A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oxaliplatin
- acid
- solution
- concentration
- container
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
Definitions
- EP 0 943 331 B1 describes a stable oxaliplatin solution with oxalic acid or an oxalic acid salt as buffer.
- the solution can be filled into an ampoule, glass vial (page 8, line 10), infusion bag or syringe. Disadvantage of this formulation is a certain toxicity of oxalic acid.
- WO 03/047 587 discloses a stable oxaliplatin solution in suitable containers (page 12, line 28) with lactic acid or a lactic acid salt as buffer.
- the present invention relates to the use of an acid to increase the solubility of oxaliplatin in an aqueous solution.
- the invention relates to a process for the preparation of an aqueous oxaliplatin solution in which oxaliplatinol is dissolved in water by adding an acid to an oxaliplatin concentration which increases over an acid-free aqueous oxaliplatin solution, in particular under otherwise identical conditions is.
- the present invention relates to a process for the preparation of a solution consisting of oxaliplatin, an acid and water, in which oxaliplatin is dissolved in water by adding an acid to an oxaliplatin concentration which is elevated over an acid-free aqueous oxaliplatin solution.
- oxaliplatin in the method of the present invention, can be dissolved in water by adding the acid to the highest oxaliplatin saturation concentration achievable with this acid.
- an oxaliplatin concentration which is in the range which is determined on the one hand by the saturation concentration of an acid-free aqueous oxaliplatin solution and on the other hand by the highest saturation concentration in the presence of the acid is defined and the acid is added until the predetermined concentration is reached.
- the solution is free from carbohydrate such as e.g. Lactose, glucose, maltose, fructose, galactose or dextrans (e.g., 10-70).
- carbohydrate such as e.g. Lactose, glucose, maltose, fructose, galactose or dextrans (e.g., 10-70).
- the solution is free of polyethylene glycol, e.g. Polyethylene glycol 200, 300, 400 and 600 added.
- an integer or half-integer (integer plus 1) oxaliplatin concentration of a customary concentration unit of measure preferably the unit of measure mg / ml or molar.
- an inorganic and / or organic acid can be used in the process according to the invention.
- At least one inorganic acid can be used from the group formed by sulfuric acid, nitric acid and phosphoric acid.
- sulfuric acid is used.
- At least one organic acid may be used from the group formed by citric acid, succinic acid, ascorbic acid, oxalic acid, lactic acid and malonic acid.
- Citric acid is preferably used.
- a buffering salt Furthermore, in the method according to the invention, it is additionally possible to use a buffering salt. Furthermore, in the method according to the invention, a pH of 1 to 7 and in particular 1.5 to 4 can be set.
- the container can be closed under an inert gas.
- a vial, a screw-cap bottle or an ampoule can be provided as a container.
- a vial as a bottle, which is designed as a single-dose or multi-dose container.
- Another embodiment of the invention relates to a container of aqueous oxaliplatin solution obtainable by the process according to the invention.
- Another embodiment of the invention relates to a container having an acidic oxaliplatin aqueous solution of an oxaliplatin concentration which is elevated relative to an acid-free oxaliplatin aqueous solution.
- a further embodiment of the invention relates to a container with an acidic aqueous oxaliplatin solution with the highest oxaliplatin saturation concentration, which is achievable with the aid of this acid, or with the highest for the acid characteristic oxaliplatin saturation concentration.
- a further embodiment of the invention relates to a container with an acidic aqueous oxaliplatin solution having an integer or half integer (integer plus M) oxaliplatin concentration of a conventional concentration unit, preferably the unit mg oxaliplatin / ml solution or mg oxaliplatin / mg solution or molar.
- a further embodiment of the invention relates to a set of or containers according to the invention each having an acidic oxaliplatin aqueous solution having an integer or integer (integer plus M) oxaliplatin concentration of a conventional concentration unit, preferably mg oxaliplatin / ml Solution or mg oxaliplatin / mg solution or molar.
- an embodiment of the invention relates to a set of or containers according to the invention each having an acidic aqueous oxaliplatin solution with an integer or half integer (integer plus M) oxaliplatin concentration of a conventional concentration unit, preferably the unit mg oxaliplatin / ml Solution or mg oxaliplatin / mg solution or molar, whereby the oxaliplatin concentration of at least one container deviates from the concentration of the other container (s).
- the present invention further comprises the solutions prepared according to one of the described methods.
- 5 examples are used to tabulate the increased oxaliplatin solubility in the presence of acid.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne un procédé pour réaliser une solution aqueuse d'oxaliplatine, selon lequel de d'oxaliplatine est dissoute dans de l'eau par ajout d'un acide jusqu'à l'obtention d'une concentration d'oxaliplatine supérieure à celle d'une solution aqueuse d'oxaliplatine sans acide. La présente invention porte également sur un contenant et un jeu de contenants avec cette solution.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/063,531 US20100140131A1 (en) | 2005-08-11 | 2006-08-11 | Production of an Oxaliplatin Mixture and a Container and a Container Set for Said Mixture |
EP06776798A EP1916996A2 (fr) | 2005-08-11 | 2006-08-11 | Realisation d'une solution d'oxaliplatine et contenant et jeu de contenants avec cette solution |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005038347A DE102005038347A1 (de) | 2005-08-11 | 2005-08-11 | Herstellung einer Oxaliplatin-Lösung und Behälter sowie Behälter-Set mit der Lösung |
DE102005038347.5 | 2005-08-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007017291A2 true WO2007017291A2 (fr) | 2007-02-15 |
WO2007017291A3 WO2007017291A3 (fr) | 2007-05-24 |
Family
ID=37179055
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/007982 WO2007017291A2 (fr) | 2005-08-11 | 2006-08-11 | Realisation d'une solution d'oxaliplatine et contenant et jeu de contenants avec cette solution |
Country Status (4)
Country | Link |
---|---|
US (1) | US20100140131A1 (fr) |
EP (1) | EP1916996A2 (fr) |
DE (1) | DE102005038347A1 (fr) |
WO (1) | WO2007017291A2 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5929607B2 (ja) * | 2012-08-06 | 2016-06-08 | ニプロ株式会社 | オキサリプラチン製剤 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999043355A2 (fr) * | 1998-02-25 | 1999-09-02 | Sanofi-Synthelabo | Formulations |
US6476068B1 (en) * | 2001-12-06 | 2002-11-05 | Pharmacia Italia, S.P.A. | Platinum derivative pharmaceutical formulations |
EP1466600A1 (fr) * | 2003-03-28 | 2004-10-13 | Stada Arzneimittel Ag | Solutions d'oxaliplatine prêtes à l'emploi |
WO2005020980A1 (fr) * | 2003-08-28 | 2005-03-10 | Mayne Pharma Pty Ltd | Formulations d'oxaliplatine contenant de l'acide |
DE102004063764A1 (de) * | 2004-12-29 | 2006-07-13 | Hexal Ag | Kunststoff-Flasche für Oxaliplatin |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002223013A1 (en) * | 2000-12-12 | 2002-06-24 | Debiopharm S.A. | Pharmaceutical oxaliplatinum preparation for parenteral administration and method for obtaining same |
CA2357955C (fr) * | 2001-09-28 | 2008-11-18 | Itf Technologies Optiques Inc./Itf Optical Technologies Inc. | Depolariseur tout fibre optique |
US20060063833A1 (en) * | 2004-09-22 | 2006-03-23 | Edgar Schridde | Ready-to-use oxaliplatin solutions |
DE102004052877B4 (de) * | 2004-11-02 | 2008-06-19 | Ebewe Pharma Ges.M.B.H. Nfg.Kg | Stabile wässrige Formulierungen eines Platin-Derivats |
-
2005
- 2005-08-11 DE DE102005038347A patent/DE102005038347A1/de not_active Withdrawn
-
2006
- 2006-08-11 US US12/063,531 patent/US20100140131A1/en not_active Abandoned
- 2006-08-11 WO PCT/EP2006/007982 patent/WO2007017291A2/fr active Application Filing
- 2006-08-11 EP EP06776798A patent/EP1916996A2/fr not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999043355A2 (fr) * | 1998-02-25 | 1999-09-02 | Sanofi-Synthelabo | Formulations |
US6476068B1 (en) * | 2001-12-06 | 2002-11-05 | Pharmacia Italia, S.P.A. | Platinum derivative pharmaceutical formulations |
US20030109515A1 (en) * | 2001-12-06 | 2003-06-12 | Pharmacia Italia, Spa. | Pharmaceutical formulation of a platinum derivative |
EP1466600A1 (fr) * | 2003-03-28 | 2004-10-13 | Stada Arzneimittel Ag | Solutions d'oxaliplatine prêtes à l'emploi |
WO2005020980A1 (fr) * | 2003-08-28 | 2005-03-10 | Mayne Pharma Pty Ltd | Formulations d'oxaliplatine contenant de l'acide |
DE102004063764A1 (de) * | 2004-12-29 | 2006-07-13 | Hexal Ag | Kunststoff-Flasche für Oxaliplatin |
Non-Patent Citations (1)
Title |
---|
See also references of EP1916996A2 * |
Also Published As
Publication number | Publication date |
---|---|
US20100140131A1 (en) | 2010-06-10 |
EP1916996A2 (fr) | 2008-05-07 |
DE102005038347A1 (de) | 2007-02-15 |
WO2007017291A3 (fr) | 2007-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69523313T2 (de) | Waessrige risperidone-zusammensetzungen | |
AT407707B (de) | Hochkonzentriertes immunglobulin-präparat und verfahren zu seiner herstellung | |
WO2002072080A2 (fr) | Solutions de paracetamol stables au stockage et pretes a la perfusion | |
DE3012058A1 (de) | Geschaeumtes gel zur behandlung unterirdischer formationen | |
DE2946724C2 (fr) | ||
AT409081B (de) | Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung | |
EP2484350B1 (fr) | Préparation pharmaceutique comprenant un complexe d'un sel de propofol et d'une cyclodextrine | |
EP2626068B1 (fr) | Paracétamol destiné à l'administration parentérale | |
DE102004021532A1 (de) | Dispersion mit insektizider Wirkung | |
WO2007017291A2 (fr) | Realisation d'une solution d'oxaliplatine et contenant et jeu de contenants avec cette solution | |
DE1067214T1 (de) | Chemikalie und verfahren zur wasserbehandlung | |
WO2006072440A1 (fr) | Bouteille en plastique conçue pour contenir une solution d'oxaliplatine | |
DE60113255T2 (de) | Neue formulierungen von -g(a)-2,4-disulfophenyl-n-tert-butylnitron | |
DE69632771T2 (de) | Menschliche therapeutische Albumin mit niedriger Aluminiumbindungsfähigkeit | |
AT392904B (de) | Verfahren zur herstellung einer zur oralen verabreichung von etoposid bestimmten weichgelantinekapsel | |
EP0900761B1 (fr) | Procédé de fabrication et de remplissage de liquides enrichis en oxygène ou enrichis d'un mélange de gaz contenant de l'oxygène et boisson obtenue par ce procédé | |
WO2006048194A1 (fr) | Preparations aqueuses stables d'un derive de platine | |
DE60006702T2 (de) | Ein verfahren zur rückgewinnung von säure | |
DE3333278A1 (de) | Verfahren zur verhinderung der weinsteinbildung in getraenken | |
EP0108248B2 (fr) | Solution aqueuse de nitroglycérine exempte de solubilisateurs | |
DE102004031538A1 (de) | Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit | |
DE102011122896A1 (de) | Rührstab | |
DE2846831B1 (de) | Duengemittelpasten und Verfahren zu deren Herstellung | |
DE102007029011A1 (de) | Verfahren zur mikrobiellen Stabilisierung von Getränken mit einem pH von größer als 4.2 mit Dialkyldicarbonaten | |
DE3338689A1 (de) | Verwendung von uronsaeuren und/oder deren derivaten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2006776798 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12063531 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2006776798 Country of ref document: EP |